Jane Street Group LLC Grows Position in Orthofix Medical Inc. (NASDAQ:OFIX)

Jane Street Group LLC grew its position in shares of Orthofix Medical Inc. (NASDAQ:OFIX) by 10.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,134 shares of the medical device company’s stock after purchasing an additional 4,647 shares during the quarter. Jane Street Group LLC owned approximately 0.13% of Orthofix Medical worth $752,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. nVerses Capital LLC purchased a new position in Orthofix Medical in the second quarter valued at $27,000. Quest Partners LLC acquired a new stake in shares of Orthofix Medical during the 2nd quarter valued at about $64,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Orthofix Medical by 25.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,435 shares of the medical device company’s stock valued at $125,000 after purchasing an additional 1,919 shares in the last quarter. Arizona State Retirement System acquired a new position in Orthofix Medical in the 2nd quarter worth about $139,000. Finally, XTX Topco Ltd purchased a new position in Orthofix Medical during the second quarter worth approximately $175,000. 89.76% of the stock is currently owned by institutional investors and hedge funds.

Orthofix Medical Price Performance

Shares of Orthofix Medical stock opened at $17.26 on Friday. The stock has a market capitalization of $659.57 million, a P/E ratio of -5.51 and a beta of 1.09. The business has a 50 day simple moving average of $18.07 and a two-hundred day simple moving average of $16.46. Orthofix Medical Inc. has a 12 month low of $12.08 and a 12 month high of $20.73. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.39 and a quick ratio of 1.11.

Analysts Set New Price Targets

OFIX has been the subject of a number of recent analyst reports. Roth Mkm restated a “buy” rating and issued a $22.00 price objective (up from $20.00) on shares of Orthofix Medical in a research report on Friday, November 8th. Stifel Nicolaus raised shares of Orthofix Medical from a “hold” rating to a “buy” rating and boosted their price target for the stock from $18.00 to $24.00 in a report on Friday, November 8th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $23.00.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.